openPR Logo
Press release

XELJANZ Poised for Remarkable Market Expansion of Ulcerative Colitis by 2032

04-01-2024 08:22 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

XELJANZ Poised for Remarkable Market Expansion of Ulcerative

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on XELJANZ (Pfizer) providing insights into the drug market landscape and market forecast of XELJANZ upto 2032. The report, titled "XELJANZ Market Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of XELJANZ in 2032? XELJANZ Market Forecast
https://www.delveinsight.com/report-store/xeljanz-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The XELJANZ Market Report offers projected sales forecasts for XELJANZ for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Pfizer's XELJANZ is serving as a beacon of hope for the patients suffering from the Ulcerative Colitis.
What is a XELJANZ Prescribed for?
Pfizer Inc. (NYSE: PFE) reported that the European Commission has granted approval for XELJANZ® (tofacitinib) 5 mg twice daily to treat adults with active ankylosing spondylitis (AS) who haven't adequately responded to conventional therapy.

The report extensively covers the details and developments related to XELJANZ, capturing important highlights on developmental pipeline, regulatory status and special designations of XELJANZ, route of administration, safety and efficacy details.

XELJANZ Market Assessment
This report provides a detailed market assessment of XELJANZ for Ulcerative Colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

XELJANZ Clinical Assessment
The report provides the clinical trials information of XELJANZ for Ulcerative Colitis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against XELJANZ? XELJANZ Drugs Insights
https://www.delveinsight.com/sample-request/xeljanz-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

XELJANZ Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the XELJANZ.

XELJANZ Market Size in the US
A dedicated section of the report focuses on the expected market size of XELJANZ for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of XELJANZ:

• The report contains forecasted sales of XELJANZ for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Ulcerative Colitis.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for XELJANZ in Ulcerative Colitis.
Stay ahead in competition by leveraging insights on XELJANZ market Report: Download XELJANZ Market Report
https://www.delveinsight.com/sample-request/xeljanz-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy XELJANZ Market Report:
• The report provides future market assessments for XELJANZ for Ulcerative Colitis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading XELJANZ for Ulcerative Colitis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XELJANZ
• Discover the competitive landscape of XELJANZ through 7MM
• Get a Thorough Analysis of the XELJANZ Development pipeline, Safety & Efficacy of the XELJANZ, and ROA
• Thorough XELJANZ market forecast will help understand how drug is competing with other emerging XELJANZ
• Get analysis of the XELJANZ clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Ulcerative Colitis Pipeline https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Ulcerative Colitis Pipeline Insight, 2024" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key Ulcerative Colitis companies in the market include - Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, Anaptys Bio, Rise Therapeutics, Merck, Altru Bio, AbbVie, Immunic AG, Kissei Pharmaceutical, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard

Latest Reports Offered By DelveInsight:

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release XELJANZ Poised for Remarkable Market Expansion of Ulcerative Colitis by 2032 here

News-ID: 3448231 • Views:

More Releases from DelveInsight Business Research

Lymphangioleiomyomatosis Market to Witness Promising Upswing by 2032, DelveInsight Forecasts
Lymphangioleiomyomatosis Market to Witness Promising Upswing by 2032, DelveInsig …
DelveInsight's "Lymphangioleiomyomatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Lymphangioleiomyomatosis, historical and forecasted epidemiology as well as the Lymphangioleiomyomatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Lymphangioleiomyomatosis, offering comprehensive insights into the Lymphangioleiomyomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Lymphangioleiomyomatosis
Progressive Supranuclear Palsy Market Expected to Gain Momentum Through 2034, According to DelveInsight
Progressive Supranuclear Palsy Market Expected to Gain Momentum Through 2034, Ac …
DelveInsight's "Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Progressive Supranuclear Palsy, offering comprehensive insights into the Progressive Supranuclear Palsy revenue trends,
Beta Thalassemia Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals
Beta Thalassemia Market Trends Point to Steady Growth Ahead by 2034, DelveInsigh …
DelveInsight's "Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Forecast https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts
Sickle Cell Disease Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review
Sickle Cell Disease Pipeline 2025: Detailed Clinical Trials and FDA-Approved The …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sickle Cell Disease pipeline constitutes 55+ key companies continuously working towards developing 60+ Sickle Cell Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.

All 5 Releases


More Releases for XELJANZ

Xeljanz Tofacitnib Drug Market By Application Analysis, Regional Outlook, Compet …
The global tofacitinib (Xeljanz) market is projected to experience significant growth over the coming years. In 2024, the market is estimated to be valued at approximately USD 3.12 billion. Looking ahead, forecasts suggest that the market could reach around USD 6.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 8.69% during the period from 2025 to 2033. Request a sample copy of this report at: https://www.omrglobal.com/request-sample/xeljanz-tofacitnib-drug-market Xeljanz Tofacitnib
Global Xeljanz Tofacitnib Drug Market Estimated to Experience a Hike in Growth b …
In 2023, the global Xeljanz (tofacitinib) market was valued at approximately USD 2.4 billion. It is projected to reach around USD 3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2032. Global Xeljanz Tofacitnib Drug Market Overview The global Xeljanz (tofacitinib) drug market is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Xeljanz,
Xeljanz (tofacitnib) Drug Consumption Market Overview with Detailed Analysis, Co …
New Jersey, United States - The Global Xeljanz (tofacitnib) Drug Consumption Marlet is comprehensively and accurately detailed in the report, taking into consideration various factors such as competition, regional growth, segmentation, and market size by value and volume. This is an excellent research study specially compiled to provide the latest insights into critical aspects of Global Xeljanz (tofacitnib) Drug Consumption. The report includes different market forecasts related to market size,
Xeljanz (tofacitnib) Drug Market Top Companies Analysis, Regional Growth Overvie …
LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Xeljanz (tofacitnib) Drug market with holistic insights into vital factors and aspects that impact future market growth. The global Xeljanz (tofacitnib) Drug market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Xeljanz (tofacitnib) Drug market and its critical dynamics, the research study
Lawsuit filed for Investors in shares of AbbVie Inc. (NYSE: ABBV)
An investor, who purchased shares of AbbVie Inc. (NYSE: ABBV), filed a lawsuit over alleged violations of Federal Securities Laws by AbbVie Inc. Investors who purchased shares of AbbVie Inc. (NYSE: ABBV) have certain options and for certain investors are short and strict deadlines running. Deadline: JUNE 6, 2022. NYSE: ABBV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Rinvoq is an anti-inflammatory drug manufactured by
Global Xeljanz Tofacitnib Drug Market, Size, Share, Analysis Report & Forecast t …
The global xeljanz tofacitnib market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor for the growth of the market is the increase in the number of arthritis patients which include patients suffering from rheumatoid arthritis, psoriatic arthritis, and ulcerative arthritis. According to the Global RA Network, around 350 million people across the globe are suffering from arthritis. Arthritis caused the US healthcare